Prot# EMR 62 225-018: A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety & Efficacy of Sarizotan HCl 1mg b.i.d. in Patients w/Parkinson's Disease Suffering from Treatment-Associated Dyskinesia (PADDY 1)

Project: Research project

Project Details

Effective start/end date11/12/049/30/06


  • Monitoring Force USA, Inc. (EMR 62 225-018)
  • Merck KGaA (EMR 62 225-018)